---
schema_version: "secwatch.filing_event.v1"
accession: "0001447362-23-000036"
form_type: "8-K"
ticker: "CSTL"
cik: "0001447362"
company_name: "CASTLE BIOSCIENCES INC"
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T21:49:02.132157+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Castle Biosciences FY2022 revenue $137M (+46% YoY); guides FY2023 revenue $170-180M

## Summary
- Full-year 2022 revenue $137.0M, up 46% from $94.1M; test reports 44,419, up 58%.
- Q4 2022 revenue $38.3M (+53% YoY); test reports 12,644 (+53%).
- Net loss $67.1M (incl. $36.3M stock compensation) vs $31.3M loss in 2021.
- Adjusted EBITDA -$42.6M vs -$14.9M; cash and investments $258.6M at year-end.
- FY2023 revenue outlook $170-180M; reaffirms 2025 targets of $255-330M revenue and cash flow positivity.

## SEC filing metadata
- accession: 0001447362-23-000036
- form_type: 8-K
- ticker: CSTL
- cik: 0001447362
- company_name: CASTLE BIOSCIENCES INC
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447362/000144736223000036/0001447362-23-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447362/000144736223000036/cstl-20230228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001447362-23-000036
- JSON: https://secwatch.observer/filing/0001447362-23-000036.json
- Plain text: https://secwatch.observer/filing/0001447362-23-000036.txt

## Key facts
- Earnings Releases
  CASTLE BIOSCIENCES INC reported financial results for the fourth quarter and year ended December 31, 2022.
  - Period: the fourth quarter and year ended December 31, 2022
  - Result: reported results
  source text: On February 28, 2023, Castle Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1447362/000144736223000036/0001447362-23-000036-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.